Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms-Reference-Cited by-同舟云学术

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Published:2013-07-02 Issue:2 Volume:28 Page:384-390
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Walker B A,Wardell C P,Melchor L,Brioli A,Johnson D C^ORCID,Kaiser M F,Mirabella F^ORCID,Lopez-Corral L,Humphray S,Murray L,Ross M,Bentley D,Gutiérrez N C,Garcia-Sanz R,San Miguel J,Davies F E,Gonzalez D,Morgan G J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013199.pdf

Reference40 articles.

1. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.

3. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM . A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418–5422.

4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

5. Morgan GJ, Walker BA, Davies FE . The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335–348.

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities;International Journal of Molecular Sciences;2024-05-10

2. IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA?;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30

3. Approach to High-Risk Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Impact of Clonal Heterogeneity in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease;Nature Communications;2024-03-19